DnaJ heat shock protein family (Hsp40) member C7Genealiases: DJ11 · DJC7 · TPR2 · TTC2
Q-omics provides the consensus-scored DNAJC7 profile across patient tissues and cancer cell-line models. DNAJC7 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, DNAJC7 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, DNAJC7 protein abundance shows 24,884 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, BLCA, and LSCC as cancer lineages where DNAJC7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNAJC7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNAJC7 survival associations across molecular data types. DNAJC7 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNAJC7 RNA expression–survival associations across cancer types. High DNAJC7 expression shows unfavorable associations in LIHC, KICH, KIRP, HNSC, UVM and ACC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for DNAJC7 RNA expression.
This table summarizes DNAJC7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in BLCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for DNAJC7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNAJC7 shows lower tumor expression in KICH and higher tumor expression in BLCA, HNSC, LIHC, STAD and LUAD. The BLCA box plot shows higher DNAJC7 RNA expression in tumor versus normal tissue (log2 FC = +0.547, t-test p < 0.001).
This table shows molecular features associated with DNAJC7 in patient tissues and cancer cell lines. In patient samples, DNAJC7 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, DNAJC7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
